Skip to main content

Advertisement

SpringerLink
Log in

Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimer’s Disease and Systemic Inflammation

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Clinically, superimposed systemic inflammation generally has significant deleterious effects on the Alzheimer’s disease (AD) progression. However, the related molecular mechanisms remain poorly understood. Microglial toll-like receptor 4 (TLR4) and triggering receptor expressed on myeloid cells 2 (TREM2) are two key regulators of inflammation that may play an essential role in this complex pathophysiological process. In this study, intraperitoneal injection of lipopolysaccharide (LPS) into APP/PS1 transgenic AD model was used to mimic systemic inflammation in the development of AD. Initial results from the cortex showed that compared with wild-type mice, APP/PS1 mice exhibited elevated gene and protein expression levels of both TLR4 and TREM2 with different degree. Interestingly, after LPS treatment, TLR4 expression was persistently up-regulated, while TREM2 expression was significantly down-regulated in APP/PS1 mice, suggesting that the negative regulatory effect of TREM2 on inflammation might be suppressed by LPS-induced hyperactive TLR4. This imbalance of TLR4/TREM2 contributed to microglial over-activation, followed by increased neuronal apoptosis in the cortex of APP/PS1 mice; these changes did not alter the expression level of Aβ1−42. Similar alterations were observed in our in vitro experiment with β-amyloid1–42 (Aβ1–42)-treated N9 microglia. Further, Morris water maze (MWM) testing data indicated that LPS administration acutely aggravated cognitive impairment in APP/PS1 mice, suggesting that the addition of systemic inflammation can potentially accelerate the progression of AD. Collectively, we conclude that an imbalance of TLR4/TREM2 may be a potential link between AD and systemic inflammation. TREM2 can serve as a potential therapeutic target for treating systemic inflammation in AD progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H (2006) The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowl Environ 2006:re1

    Article  Google Scholar 

  2. Wang M, Li Y, Ni C, Song G (2017) Honokiol attenuates oligomeric amyloid beta1-42-induced Alzheimer’s disease in mice through attenuating mitochondrial apoptosis and inhibiting the nuclear factor Kappa-B signaling pathway. Cell Physiol Biochem 43:69–81

    Article  CAS  PubMed  Google Scholar 

  3. Amin FU, Hoshiar AK, Do TD, Noh Y, Shah SA, Khan MS, Yoon J, Kim MO (2017) Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer’s disease. Nanoscale 9:10619–10632

    Article  CAS  PubMed  Google Scholar 

  4. Cruchaga C, Kauwe John SK, Harari O, Jin Sheng C, Cai Y, Karch Celeste M, Benitez Bruno A, Jeng Amanda T, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman Joshua M, De Jager Philip L, Chibnik L, Bennett David A, Arnold Steve E, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin Vivianna M, Lee Virginia MY, Shaw Leslie M, Trojanowski John Q, Haines Jonathan L, Mayeux R, Pericak-Vance Margaret A, Farrer Lindsay A, Schellenberg Gerard D, Peskind Elaine R, Galasko D, Fagan Anne M, Holtzman David M, Morris John C, Goate Alison M (2013) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. Neuron 78:256–268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Khan SS, Bloom GS (2016) Tau: the center of a signaling nexus in Alzheimer’s disease. Front Neurosci 10:31

    PubMed  PubMed Central  Google Scholar 

  6. Lanoiselee HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard AC, Pasquier F, Rollin-Sillaire A, Martinaud O, Quillard-Muraine M, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauvire V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, Felician O, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Chamard L, Vincent JL, Sauvee M, Marelli-Tosi C, Gabelle A, Ozsancak C, Pariente J, Paquet C, Hannequin D, Campion D, Collaborators of the CNRMAJp (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med 14:e1002270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Agosta F, Dalla Libera D, Spinelli EG, Finardi A, Canu E, Bergami A, Bocchio Chiavetto L, Baronio M, Comi G, Martino G, Matteoli M, Magnani G, Verderio C, Furlan R (2014) Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. Ann Neurol 76:813–825

    Article  CAS  PubMed  Google Scholar 

  8. Sanabria-Castro A, Alvarado-Echeverria I, Monge-Bonilla C (2017) Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci 24:46–54

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer’s disease. Neurobiol Dis 37:503–509

    Article  CAS  PubMed  Google Scholar 

  10. Latta CH, Brothers HM, Wilcock DM (2015) Neuroinflammation in Alzheimer’s disease; a source of heterogeneity and target for personalized therapy. Neuroscience 302:103–111

    Article  CAS  PubMed  Google Scholar 

  11. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1:1003

    PubMed  PubMed Central  Google Scholar 

  12. Murray CL, Skelly DT, Cunningham C (2011) Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6. J Neuroinflamm 8:50

    Article  CAS  Google Scholar 

  13. Goldeck D, Witkowski JM, Fulop T, Pawelec G (2016) Peripheral immune signatures in Alzheimer disease. Curr Alzheimer Res 13:739–749

    Article  CAS  PubMed  Google Scholar 

  14. Perry VH, Cunningham C, Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7:161–167

    Article  CAS  PubMed  Google Scholar 

  15. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE (2001) Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res Bull 56:581–588

    Article  CAS  PubMed  Google Scholar 

  17. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci 25:8843–8853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158:63–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P (2012) Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 120:461–472

    Article  CAS  PubMed  Google Scholar 

  20. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9:429–439

    Article  CAS  PubMed  Google Scholar 

  21. Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol 88:594–604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huang NQ, Jin H, Zhou SY, Shi JS, Jin F (2017) TLR4 is a link between diabetes and Alzheimer’s disease. Behav Brain Res 316:234–244

    Article  CAS  PubMed  Google Scholar 

  23. Buchanan MM, Hutchinson M, Watkins LR, Yin H (2010) Toll-like receptor 4 in CNS pathologies. J Neurochem 114:13–27

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Arroyo DS, Soria JA, Gaviglio EA, Rodriguez-Galan MC, Iribarren P (2011) Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 11:1415–1421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shi S, Liang D, Chen Y, Xie Y, Wang Y, Wang L, Wang Z, Qiao Z (2016) Gx-50 reduces β-amyloid-induced TNF-α, IL-1β, NO, and PGE2expression and inhibits NF-κB signaling in a mouse model of Alzheimer’s disease. Eur J Immunol 46:665–676

    Article  CAS  PubMed  Google Scholar 

  26. Dean JM, Wang X, Kaindl AM, Gressens P, Fleiss B, Hagberg H, Mallard C (2010) Microglial MyD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro. Brain Behav Immun 24:776–783

    Article  CAS  PubMed  Google Scholar 

  27. Kawai T, Akira S (2007) Signaling to NF-kappaB by toll-like receptors. Trends Mol Med 13:460–469

    Article  CAS  PubMed  Google Scholar 

  28. Ito H, Hamerman JA (2012) TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 42:176–185

    Article  CAS  PubMed  Google Scholar 

  29. Zhong L, Chen XF, Zhang ZL, Wang Z, Shi XZ, Xu K, Zhang YW, Xu H, Bu G (2015) DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response. J Biol Chem 290:15866–15877

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trümbach D, Wurst W, Brunner B, Bultmann S, Tahirovic S, Kerschensteiner M, Misgeld T, Butovsky O, Haass C (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. https://doi.org/10.15252/embr.201743922

    Article  PubMed  PubMed Central  Google Scholar 

  31. Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8:992–1004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56:1438–1447

    Article  PubMed  Google Scholar 

  33. Carrasquillo MM, Allen M, Burgess JD, Wang X, Strickland SL, Aryal S, Siuda J, Kachadoorian ML, Medway C, Younkin CS, Nair A, Wang C, Chanana P, Serie D, Nguyen T, Lincoln S, Malphrus KG, Morgan K, Golde TE, Price ND, White CC, De Jager PL, Bennett DA, Asmann YW, Crook JE, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N (2016) A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer’s disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimers Dement 13:663–673

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hu N, Tan MS, Yu JT, Sun L, Tan L, Wang YL, Jiang T, Tan L (2014) Increased expression of TREM2 in peripheral blood of Alzheimer’s disease patients. J Alzheimers Dis 38:497–501

    Article  CAS  PubMed  Google Scholar 

  35. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. New Engl J Med 368:107–116

    Article  CAS  PubMed  Google Scholar 

  36. Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X, Rumbaugh M, Matsushita M, Girirajan S, Dorschner MO, Kiianitsa K, Yu CE, Brkanac Z, Garden GA, Raskind WH, Bird TD (2015) R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol 72:920–927

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M (2017) TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170:649–663.e613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis G (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127

    Article  CAS  PubMed  Google Scholar 

  39. Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V (2015) The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer’s dementia. Alzheimers Dement 11:1163–1170

    Article  PubMed  Google Scholar 

  40. Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Mol Neurodegener 11:3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Ulrich JD, Ulland TK, Colonna M, Holtzman DM (2017) Elucidating the role of TREM2 in Alzheimer’s disease. Neuron 94:237–248

    Article  CAS  PubMed  Google Scholar 

  42. Jiang T, Yu J-T, Zhu X-C, Tan L (2013) TREM2 in Alzheimer’s disease. Mol Neurobiol 48:180–185

    Article  CAS  PubMed  Google Scholar 

  43. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K (2006) Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 129:3006–3019

    Article  PubMed  Google Scholar 

  44. Combs C, Chen Y-C, Yip P-K, Huang Y-L, Sun Y, Wen L-L, Chu Y-M, Chen T-F (2012) Sequence variants of toll like receptor 4 and late-onset Alzheimer’s disease. PLoS ONE 7:e50771

    Article  CAS  Google Scholar 

  45. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 20:947–956

    Article  CAS  PubMed  Google Scholar 

  46. Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177:3520–3524

    Article  CAS  PubMed  Google Scholar 

  47. Gawish R, Martins R, Bohm B, Wimberger T, Sharif O, Lakovits K, Schmidt M, Knapp S (2015) Triggering receptor expressed on myeloid cells-2 fine-tunes inflammatory responses in murine Gram-negative sepsis. FASEB J 29:1247–1257

    Article  CAS  PubMed  Google Scholar 

  48. Jiang T, Yu J-T, Zhu X-C, Tan M-S, Gu L-Z, Zhang Y-D, Tan L (2014) Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35:1243–1251

    Article  CAS  PubMed  Google Scholar 

  49. Zou Y, Li Y, Yu W, Du Y, Shi R, Zhang M, Duan J, Deng Y, Tu Q, Dai R, Lu Y (2013) Hypoxia-up-regulated mitochondrial movement regulator does not contribute to the APP/PS1 double transgenic mouse model of Alzheimer’s disease. Dement Geriatr Cogn Disord 36:137–145

    Article  CAS  PubMed  Google Scholar 

  50. Lim H-S, Kim YJ, Kim B-Y, Park G, Jeong S-J (2018) The anti-neuroinflammatory activity of tectorigenin pretreatment via downregulated NF-κB and ERK/JNK pathways in BV-2 microglial and microglia inactivation in mice with lipopolysaccharide. Front Pharmacol 9:462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Han Y-G, Qin X, Zhang T, Lei M, Sun F-Y, Sun J-J, Yuan W-F (2018) Electroacupuncture prevents cognitive impairment induced by lipopolysaccharide via inhibition of oxidative stress and neuroinflammation. Neurosci Lett 683:190–195

    Article  CAS  PubMed  Google Scholar 

  52. Xiao Q, Yu W, Tian Q, Fu X, Wang X, Gu M, Lu Y (2017) Chitinase1 contributed to a potential protection via microglia polarization and Abeta oligomer reduction in d-galactose and aluminum-induced rat model with cognitive impairments. Neuroscience 355:61–70

    Article  CAS  PubMed  Google Scholar 

  53. Liu HC, Zheng MH, Du YL, Wang L, Kuang F, Qin HY, Zhang BF, Han H (2012) N9 microglial cells polarized by LPS and IL4 show differential responses to secondary environmental stimuli. Cell Immunol 278:84–90

    Article  CAS  PubMed  Google Scholar 

  54. Qiao R, Li S, Zhou M, Chen P, Liu Z, Tang M, Zhou J (2017) In-depth analysis of the synaptic plasma membrane proteome of small hippocampal slices using an integrated approach. Neuroscience 353:119–132

    Article  CAS  PubMed  Google Scholar 

  55. Chen Z, Jalabi W, Shpargel KB, Farabaugh KT, Dutta R, Yin X, Kidd GJ, Bergmann CC, Stohlman SA, Trapp BD (2012) Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 32:11706–11715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Yin Z, Raj D, Saiepour N, Van Dam D, Brouwer N, Holtman IR, Eggen BJL, Moller T, Tamm JA, Abdourahman A, Hol EM, Kamphuis W, Bayer TA, De Deyn PP, Boddeke E (2017) Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer’s disease. Neurobiol Aging 55:115–122

    Article  CAS  PubMed  Google Scholar 

  57. Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213:667–675

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Mouton PR, Kelley-Bell B, Tweedie D, Spangler EL, Perez E, Carlson OD, Short RG, deCabo R, Chang J, Ingram DK, Li Y, Greig NH (2012) The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons. Neurobiol Aging 33:423 e427–e436

    Article  CAS  Google Scholar 

  59. Liu Y-C, Gao X-X, Chen L, You X-q (2017) Rapamycin suppresses Aβ 25–35- or LPS-induced neuronal inflammation via modulation of NF-κB signaling. Neuroscience 355:188–199

    Article  CAS  PubMed  Google Scholar 

  60. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG (2015) TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol 25:469–480

    Article  CAS  PubMed  Google Scholar 

  61. Takahashi K, Rochford CDP, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647–657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Jones BM, Bhattacharjee S, Dua P, Hill JM, Zhao Y, Lukiw WJ (2014) Regulating amyloidogenesis through the natural triggering receptor expressed in myeloid/microglial cells 2 (TREM2). Front Cell Neurosci 8:94

    PubMed  PubMed Central  Google Scholar 

  63. Hickman SE, El Khoury J (2014) TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88:495–498

    Article  CAS  PubMed  Google Scholar 

  64. Zhang Q, Wu H-h, Wang Y, Gu G-j, Zhang W, Xia R (2016) Neural stem cell transplantation decreases neuroinflammation in a transgenic mouse model of Alzheimer’s disease. J Neurochem 136:815–825

    Article  CAS  PubMed  Google Scholar 

  65. Ulrich JD, Finn M, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM (2014) Altered microglial response to Aβ plaques in APPPS1–21 mice heterozygous for TREM2. Mol Neurodegener 9:20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918–934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:38–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Whittaker GC, Orr SJ, Quigley L, Hughes L, Francischetti IM, Zhang W, McVicar DW (2010) The linker for activation of B cells (LAB)/non-T cell activation linker (NTAL) regulates triggering receptor expressed on myeloid cells (TREM)-2 signaling and macrophage inflammatory responses independently of the linker for activation of T cells. J Biol Chem 285:2976–2985

    Article  CAS  PubMed  Google Scholar 

  69. Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, Gu LZ, Wang HF, Ding ZZ, Zhang YD, Yu JT (2014) Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology 39:2949–2962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Jay TR, von Saucken VE, Landreth GE (2017) TREM2 in neurodegenerative diseases. Mol Neurodegener 12:56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58:253–263

    PubMed  Google Scholar 

  72. Zhao Y, Jaber V, Lukiw WJ (2016) Over-expressed pathogenic miRNAs in Alzheimer’s disease (AD) and prion disease (PrD) drive deficits in TREM2-mediated Aβ42 peptide clearance. Front Aging Neurosci 8:140

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank AJE (http://www.aje.com/) for English language editing and proofreading this manuscript. This work was supported by Grants from the Chongqing Natural Science Foundation (cstc2018jcyjAX0169), the National Natural Science Foundation of China (81671286, 31570826), the National Key Clinical Specialties Construction Program of China (No. [2013]544), and the Application Program of the Chongqing Science & Technology Commission (cstc2014yykfA110002).

Author information

Author notes

  1. Jian Zhou, Weihua Yu and Man Zhang contributed equally to this work.

Authors and Affiliations

  1. Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, 400016, China

    Jian Zhou, Weihua Yu, Man Zhang & Yang Lü

  2. Institute of Neuroscience, Chongqing Medical University, Chongqing, 400016, China

    Jian Zhou & Weihua Yu

  3. Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

    Xin Tian

  4. Department of Pathology, Chongqing Medical University, Chongqing, 400016, China

    Yu Li

Authors
  1. Jian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weihua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Man Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Lü
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yang Lü.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

11064_2019_2748_MOESM1_ESM.pdf

Supplementary material 1 Supplementary Figure S1. Localization analysis for TREM2 (green) and TLR4 (red) in the cortex of WT mice using immunofluorescence double-labeling. TREM2 and TLR4 were expressed on the surface of microglia. Scale bar: 20 μm. Supplementary Figure S2. Detailed comparison of the escape latency on the navigation test on days 1, 2, 3, 4, 5 and 7. *Significant compared with the WT group (p < 0.05); #Significant compared with the APP/PS1 group (p < 0.05); ▲Significant compared with the WT+LPS group (p < 0.05). (PDF 209 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Yu, W., Zhang, M. et al. Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimer’s Disease and Systemic Inflammation. Neurochem Res 44, 1138–1151 (2019). https://doi.org/10.1007/s11064-019-02748-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-019-02748-x

Keywords

Search

Navigation